Brief: Lantern Pharma Leverages AI Platform, RADR, To Develop Breakthrough ADCS In Collaboration With Bielefeld University
08/06/2023 15:02
June 8 (Reuters) - Lantern Pharma Inc LTRN.O :
* LANTERN PHARMA LEVERAGES AI PLATFORM, RADR®, TO DEVELOP
BREAKTHROUGH ANTIBODY DRUG CONJUGATES (ADCS) IN COLLABORATION
WITH BIELEFELD UNIVERSITY
* LANTERN PHARMA - CRYPTOPHYCIN-ANTIBODY DRUG CONJUGATES
WILL BE
TESTED ACROSS MULTIPLE CANCER CELL LINES AND INITIAL RESULTS ARE
EXPECTED DURING 2023
Source text for Eikon: ID:nBwc3Yg0Na
Further company coverage: LTRN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lantern Pharma
See all newsBrief: Lantern Pharma Reports HARMONIC Data Showing LP-300 Progression-Free Survival Benefit Deepens With Treatment Duration In EGFR Exon 21 L858R Lung Cancer
Brief: Lantern Pharma Announces Successful Outcome Of FDA Type C Meeting Request For Harmonic Phase 2 Trial of LP-300 In Never-Smokers With NSCLC
Lantern Pharma Q1 net loss narrows on R&D cost cuts
Brief: Lantern Pharma Inc. Announces Up To $9.25 Million Registered Direct Offering With Existing Holders And A Single Institutional Investor
Brief: Lantern Pharma Inc - Schedules Type C FDA Meeting For Harmonic Protocol Amendments